CSL312

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
85	特発性間質性肺炎	2

85. 特発性間質性肺炎

臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-003162-12-DK (EUCTR)	21/04/2022	10/12/2021	CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis	A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, a ...	Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idio ...	Product Name: Factor XIIa antagonist monoclonal antibody Product Code: CSL312Garadacimab INN or Propos ...	CSL Behring LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	80	Phase 2	United States;Czechia;Spain;Ukraine;Lithuania;Austria;United Kingdom;Italy;Switzerland;France;Canada ...
2	NCT05130970 (ClinicalTrials.gov)	January 27, 2022	12/11/2021	CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis	A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, a ...	Idiopathic Pulmonary Fibrosis	Drug: CSL312;Drug: Placebo	CSL Behring	NULL	Recruiting	40 Years	N/A	All	80	Phase 2	United States;Australia;Austria;Belgium;Canada;Denmark;Germany;Poland;Spain;United Kingdom

First Previous1Next Last